Topical Clindamycin For Acne Vulgaris: Pharmacovigilance Safety Review and Retrospective Analysis of Gastrointestinal Events
Main Article Content
Keywords
clindamycin phosphate, inflammatory bowel disease, colitis, safety, topical, acne vulgaris
Abstract
Background: Clindamycin, a lincosamide antibiotic, was the 125th most prescribed medicine in the US in 2020. Topical formulations that combine clindamycin with benzoyl peroxide or a retinoid are commonly used for acne vulgaris (AV) treatment. While oral and topical clindamycin carry warnings/contraindications regarding the development of gastrointestinal (GI) adverse events (AEs), the real-world incidence of these AEs with topical clindamycin is unknown. The objective is to provide an overview of safety data for topical clindamycin when used for AV treatment.
Methods: Safety data from published literature on PubMed® (case reports, clinical trials data, retrospective data), previously unpublished worldwide pharmacovigilance data (from January 1, 1900-December 31, 2022), and two unpublished retrospective cohort studies of US electronic medical records (EMR; January 1, 2011 to January 31, 2019) were reviewed, with a focus on inflammatory bowel disease (IBD) and GI AEs following topical clindamycin monotherapy or combination treatment
Results: There have been only 4 published case reports of topical clindamycin-associated GI AEs, which were all published between the years 1981-1997. In 8 published pivotal phase 3 clinical trials of topical clindamycin monotherapy or combination treatment for AV, GI-related AEs were reported in 1.4% of clindamycin-treated participants (38/2,672; safety populations). According to the pharmacovigilance data, the rate of GI-related adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). In 1 published retrospective report, there were 0 reports of colitis from the 1,124 patients estimated to have received topical clindamycin prescriptions in the years 1977-1980. In the first retrospective EMR study, results indicate that physicians prescribe topical clindamycin for AV treatment equally to patients with a history of IBD (19.0%; 98/515) or without (20.7%; 14,495/70,151). The second retrospective EMR study showed that among patients with AV and an initial prescription for topical clindamycin (monotherapy or combination; n=18,012), there were 3 (0.02%) incident cases of pseudomembranous colitis within 30 days; none of these cases had a history of IBD.
Conclusions: A review of published case reports, clinical trials safety data, worldwide pharmacovigilance data, and retrospective US prescription data demonstrate that GI events—including colitis or pseudomembranous colitis—in patients exposed to topical clindamycin is extremely low, regardless of IBD history.
Support: Ortho Dermatologics
References
2. ClinCalc DrugStats database. https://clincalc.com/DrugStats/Drugs/Clindamycin.
3. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/.
4. Zaenglein AL et al. J Am Acad Dermatol. 2016;74(5):945-973.
5. CLEOCIN HCl® [package insert]. Pfizer. 2022.
6. CLEOCIN-T® [monograph]. Pfizer. 2019.
7. CLINDAGEL® [monograph]. Clindagel, LLC. 2000.
8. EVOCLIN® [package insert]. Mylan Pharmaceuticals. 2010.
9. Parry MF & Rha CK. Arch Dermatol. 1986;122(5):583-584.
10. Milstone EB, et al. Arch Dermatol. 1981;117(3):154-155.
11. Schiedermayer DL & Loo FD. Wis Med J. 1987;86(3):29-30.
12. Gallerani M, et al. Clin Drug Investigation. 1997;14:243-245.
13. Stergachis A, et al. West J Med. 1984;140(2):217-219.
14. Pariser DM, et al. J Drugs Dermatol. 2014;13(9):1083-1089.
15. US FDA. NDA-050-741. 2002. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50741_DUAC%20Topical%20Gel_Medr_P1.pdf.
16. US FDA. NDA-050-803. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050803Orig1s000MedR.pdf.
17. US FDA. NDA-050-801. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/050801s000_Evoclin_MedR.pdf.
18. Data on file, Bausch Health Americas, Inc. Studies V01-126A-301and V01-126A-302.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.